A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

Overview

The objective of this non-interventional, observational study is to assess the effectiveness and patient reported outcome of adalimumab in patients with moderate to severe psoriasis in real world clinical practice in China.

Full Title of Study: “Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 25, 2020

Arms, Groups and Cohorts

  • Participants with moderate to severe plaque psoriasis in China
    • Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of patients achieving at least a 75% reduction in Psoriasis Area Severity Index (PASI) relative to the baseline PASI score
    • Time Frame: At Week 12
    • PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination.

Secondary Measures

  • Change from Baseline in Dermatology Life Quality Index (DLQI)
    • Time Frame: From Week 0 to Week 12
    • The DLQI is a self administered short, simple and practical dermatology-specific quality of life (QoL) questionnaire.

Participating in This Clinical Trial

Inclusion Criteria

  • Participant who is in compliance with eligibility for adalimumab based on the local label; – Moderate to severe plaque psoriasis patients eligible to use adalimumab according to the local label without any contraindication – Patients have signed the authorization (or informed consent where applicable) to disclose and use personal health information after been prescribed with adalimumab. Exclusion Criteria:

  • Patients who are pregnant or breast feeding at enrolment or wish to become pregnant during the following adalimumab treatment and within 150 days since adalimumab discontinuation; – Patients in any psoriasis related clinical trial at the time of enrolment, at baseline or at any point during the study follow-up; – Patients with active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) as well as moderate to severe cardiac insufficiency. – Patients with difficulties for adequately reading, understanding and completing patient questionnaires.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AbbVie
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • AbbVie Inc., Study Director, AbbVie

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.